Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [mAbcam 190886] to N6-methyladenosine (m6A) - BSA and Azide free
- Suitable for: Nucleotide Array
- Reacts with: Human
Product nameAnti-N6-methyladenosine (m6A) antibody [mAbcam 190886] - BSA and Azide free
See all N6-methyladenosine (m6A) primary antibodies
DescriptionRabbit monoclonal [mAbcam 190886] to N6-methyladenosine (m6A) - BSA and Azide free
Tested applicationsSuitable for: Nucleotide Arraymore details
Species reactivityReacts with: Human
Chemical/ Small Molecule corresponding to N6-methyladenosine (m6A) conjugated to keyhole limpet haemocyanin.
- ab190886 was tested on a oligonucleotide array against RNA oligomers; N6-methyladenosine (m6A) and unmodified adenosine. 2Ome-RNA oligomers carry a methyl group at the 2’-OH residue of the ribose molecule, making them resistant to most ribonucleases.
N6-methyladenosine (m6A) is a post-transcriptional modification of RNA. m6A modification has been identified in all classes of RNA (rRNA, tRNA and mRNA) and is catalysed by an evolutionary conserved multi-subunit enzyme, methyltransferase like 3 (METTL3). Cellular and viral RNA has been known to be methylated for decades. Recent studies have found that mRNA is predominately m6A modified at stop codons and long internal exons, which are conserved between mouse and human. Emerging evidence suggests m6A plays an important role in regulating gene expression, alternative splicing patterns, downstream signalling (p53) as well as apoptosis.
The regulation of m6A modifications in mRNA has been linked to disease, where fat mass and obesity-associated (FTO) has been has been reported to be a obesity risk gene. FTO is a m6A demethylase and polymorphisms that result in increased FTO expression are associated with increased body mass and risk of obesity.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
PBS prepared using DEPC-treated water.
The use of RNase inhibitor is recommended.
Concentration information loading...
PurityProtein A purified
Clone numbermAbcam 190886
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab190886 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 2 µg/ml.
Use a concentration of 2 µg/ml.
RelevanceN6-Methyladenosine (m6A) is an abundant modification found in mRNA, tRNA, snRNA, as well as long non-coding RNA, in all species. RNA adenosine methylation is catalyzed by a multicomponent complex composed of METTL3/MT-A70, METTL14, and WTAP in mammals. METTL3 & METTL14 are responsible for the methyltransferase activity of the complex, and WTAP mediates substrate recruitment.
- m6A antibody
- N6-methyladenosine antibody
All batches of ab190886 are tested in Nucleotide Array against N6-methyladenosine and unmodified adenosine. Six dilutions of each oligomer are printed on to the Array in triplicate and results are averaged before being plotted on to a graph. Results show strong binding to N6-methyladenosine, indicating that this antibody specifically recognises adenosine methylated at position N6.
2Ome-m6A - N6-methyladenosine
2Ome-m6A_unmod - unmodified adenosine
ab190886 has been referenced in 8 publications.
- Duda KJ et al. m6A RNA methylation of major satellite repeat transcripts facilitates chromatin association and RNA:DNA hybrid formation in mouse heterochromatin. Nucleic Acids Res 49:5568-5587 (2021). PubMed: 33999208
- Martinez De La Cruz B et al. Modifying the m6A brain methylome by ALKBH5-mediated demethylation: a new contender for synaptic tagging. Mol Psychiatry N/A:N/A (2021). PubMed: 34663904
- Yang X et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer 19:46 (2020). PubMed: 32111213
- Yang YW et al. Ascorbic acid promotes the reproductive function of porcine immature Sertoli cells through transcriptome reprogramming. Theriogenology 158:309-320 (2020). PubMed: 33007716
- Lobo J et al. m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance. J Transl Med 17:79 (2019). PubMed: 30866959
- Zhuang M et al. The m6A reader YTHDF1 regulates axon guidance through translational control of Robo3.1 expression. Nucleic Acids Res 47:4765-4777 (2019). PubMed: 30843071
- Mauer J et al. FTO controls reversible m6Am RNA methylation during snRNA biogenesis. Nat Chem Biol 15:340-347 (2019). PubMed: 30778204
- Patil DP et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537:369-373 (2016). RIP ; Human . PubMed: 27602518